SCHEMBL16626416

SCHEMBL16626416

CNCc1cn(S(=O)(=O)c2cccnc2)c2cc(Nc3ccc(Br)cc3OC(F)(F)F)ccc12

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALPL P05186 4/20 0.42
KDR P35968 1/20 0.37
NAMPT P43490 5/20 0.35
IDE P14735 1/20 0.34
HTR6 P50406 4/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
SLC40A1 Q9NP59 1/20 0.32
IDH1 O75874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16618861 0.99 ALPL (0.41) ALPLKDRNAMPTIDEHTR6
SCHEMBL16626427 0.90 HTR6 (0.40) NAMPTHTR6LMNAHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL16618642 0.90 HTR6 (0.40) NAMPTHTR6LMNAHTTSMN1; SMN2
SCHEMBL16626411 0.88 IDE (0.35) NAMPTIDEHTR6PTGS1PTGS2
Hydrochloric Acid SCHEMBL16618649 0.88 IDE (0.34) NAMPTIDEHTR6PTGS1PTGS2
SCHEMBL16626439 0.87 LMNA (0.39) ALPLKDRNAMPTHTR6LMNA
Hydrochloric Acid SCHEMBL16619117 0.87 LMNA (0.38) ALPLKDRNAMPTHTR6LMNA
SCHEMBL16626436 0.86 HTR6 (0.38) NAMPTIDEHTR6PTGS1PTGS2
SCHEMBL16626675 0.86 HTT (0.38) NAMPTIDEHTR6HTTPTGS1
Hydrochloric Acid SCHEMBL16618724 0.86 HTR6 (0.37) NAMPTIDEHTR6PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI ALPL 1900/4885KDR 4863/4885NAMPT 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.